Compare LEGH & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEGH | SLDB |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | 121 |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 691.6M | 781.7M |
| IPO Year | 2018 | 2017 |
| Metric | LEGH | SLDB |
|---|---|---|
| Price | $28.94 | $6.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $25.00 | $16.36 |
| AVG Volume (30 Days) | 62.6K | ★ 993.4K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.97 |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $164,567,000.00 | $8,094,000.00 |
| Revenue This Year | $11.90 | N/A |
| Revenue Next Year | $6.58 | N/A |
| P/E Ratio | $20.22 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.29 | $3.79 |
| 52 Week High | $31.34 | $11.45 |
| Indicator | LEGH | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 59.22 | 27.63 |
| Support Level | $28.00 | $6.76 |
| Resistance Level | $30.92 | $7.26 |
| Average True Range (ATR) | 0.90 | 0.48 |
| MACD | 0.12 | -0.24 |
| Stochastic Oscillator | 76.11 | 2.64 |
Legacy Housing Corp builds, sells, and finances manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores, and are also sold directly to manufactured home communities. The Company manufactures and provides for the transport of manufactured homes, provides wholesale financing to dealers and mobile home parks, provides retail financing to consumers, and is involved in financing and developing new manufactured home communities. The Company manufactures its mobile homes at plants in Fort Worth, Texas; Commerce, Texas; and Eatonton, Georgia. The Company also sells homes directly to consumers, through its own retail stores, and to dealers and mobile home parks.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.